Nasdaq:US$9.09 (+0.33) | HKEX:HK$13.58 (+0.36) | AIM:£1.58 (+0.06)
News & Presentations
Previous Article   |   Next Article
Presentations | 22 Jan 2022

ASCO GI 2022 | Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer